PMID- 8405501
OWN - NLM
STAT- MEDLINE
DCOM- 19931109
LR  - 20191023
IS  - 0950-821X (Print)
IS  - 0950-821X (Linking)
VI  - 7
IP  - 5
DP  - 1993 Sep
TI  - A randomised controlled trial of a low-molecular-weight heparin (Enoxaparin) to 
      prevent deep-vein thrombosis in patients undergoing vascular surgery.
PG  - 554-60
AB  - The incidence of postoperative deep vein thrombosis (PDVT) after aortic surgery 
      and lower limb revascularisation has not been assessed by a large prospective 
      study. In a prospective randomised trial the effect of a low-molecular-weight 
      heparin fragment, Enoxaparin (ENX) 4200 anti factor Xa IU once daily was compared 
      to that of unfractionated heparin (UFH) 7500 IU twice daily. Two hundred and 
      thirty-three consecutive patients were classified into three groups, aortic or 
      aortoiliac and aneurysmectomy (n = 75), aorto-femoral bypass for atherosclerotic 
      disease (n = 71), and femoropopliteal or femorodistal bypass (n = 87). Patients 
      were analysed for development of deep vein thrombosis by Duplex scanning and, if 
      positive, by venography between the seventh and tenth postoperative day. PDVT was 
      present in 10 patients in the ENX group and in four patients in the UFH group 
      (8.2 and 3.6% respectively, NS). The incidence of PDVT was 8% after aortic or 
      aortoiliac aneurysmectomy, 7% after aortofemoral revascularisation, and 3.4% 
      after femoropopliteal or femorodistal bypass. The overall incidence of PDVT after 
      aortic surgery was 7.5% (95% CI 5.4-9.7). There was no pulmonary embolism. 
      Intra-operative blood loss and postoperative bleeding events did not differ 
      significantly between the ENX and UFH groups. After 1 month follow-up, no 
      clinical event or death could be related to PDVT or pulmonary embolism. In 
      conclusion, in vascular surgery ENX is as safe and effective in the prevention of 
      PDVT as is UFH.
FAU - Farkas, J C
AU  - Farkas JC
AD  - Department of Vascular Surgery, Hopital Saint-Joseph, Paris, France.
FAU - Chapuis, C
AU  - Chapuis C
FAU - Combe, S
AU  - Combe S
FAU - Silsiguen, M
AU  - Silsiguen M
FAU - Marzelle, J
AU  - Marzelle J
FAU - Laurian, C
AU  - Laurian C
FAU - Cormier, J M
AU  - Cormier JM
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Eur J Vasc Surg
JT  - European journal of vascular surgery
JID - 8709440
RN  - 0 (Enoxaparin)
RN  - 9005-49-6 (Heparin)
SB  - IM
MH  - Aged
MH  - Aorta, Abdominal/surgery
MH  - Double-Blind Method
MH  - Enoxaparin/adverse effects/*therapeutic use
MH  - Female
MH  - Heparin/adverse effects/therapeutic use
MH  - Humans
MH  - Leg/blood supply
MH  - Male
MH  - Middle Aged
MH  - Prospective Studies
MH  - Risk Factors
MH  - Thrombophlebitis/etiology/*prevention & control
MH  - Vascular Surgical Procedures/*adverse effects
EDAT- 1993/09/01 00:00
MHDA- 1993/09/01 00:01
CRDT- 1993/09/01 00:00
PHST- 1993/09/01 00:00 [pubmed]
PHST- 1993/09/01 00:01 [medline]
PHST- 1993/09/01 00:00 [entrez]
AID - 10.1016/s0950-821x(05)80369-x [doi]
PST - ppublish
SO  - Eur J Vasc Surg. 1993 Sep;7(5):554-60. doi: 10.1016/s0950-821x(05)80369-x.